• NICE recommends Incyte’s Pemazyre for rare bile duct cancer pharmatimes
    July 23, 2021
    The UK’s National Institute for Health and Care Excellence (NICE) has issued a positive recommendation for Incyte Biosciences UK’s Pemazyre for the treatment of the rare bile duct cancer cholangiocarcinoma (CCA).
  • Senhwa Biosciences Presents Positive Cholangiocarcinoma Data prnasia
    January 18, 2021
    Senhwa Biosciences, Inc., a clinical-stage biopharmaceutical company focused on next generation DNA Damage Response (DDR) therapeutics for the treatment of cancer, announces that promising clinical data from their global phase 1b/2 trial, evaluating ...
PharmaSources Customer Service